FMRP – the protein behind immunotherapy resistance
Immunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system…
The gene-editing tool CRISPR-Cas9 has taken over the life sciences world since its development in 2012. CRISPR has changed the way biology research is done, simplifying and speeding up the study of diseases and the discovery of drugs, as well as having a huge impact on crop and food development. Among all its possible applications, the fact that CRISPR can be used to tweak the human genome has made it especially promising for previously difficult-to-treat diseases.
But how does CRISPR work? What kind of therapies are being developed? How is the genome-editing market evolving? And how are stakeholders navigating the complex intellectual property around this technology? Find out the answers to these questions and more on this page.
The Genome Editing Toolbox: ZFNS, TALENS, and CRISPR in Biomedicine
This report covers the industry’s most common genome-editing tools, like CRISPR-Cas9, provides exclusive insights by experts, looks at the market, and addresses future applications and challenges of genome-editing tools.
Go to ReportImmunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system…
PACT Pharma, Inc. has reported data from the first clinical study using CRISPR gene editing…
Two companies with sole rights to two CRISPR diagnostic methods in markets outside the U.S.…
Neil Ward, general manager of PacBio EMEA With applications of CRISPR across the spectrum of…
Monika Paulė, CEO and co-founder of the Lithuanian CRISPR developer Caszyme, explains how gene editing…
A team of researchers at U.S. Northwestern University has developed a way to transform the…
Metastatic prostate cancer is a leading cause of cancer death in men worldwide. Interleukin (IL)-30,…
PerkinElmer’s Horizon Discovery provides cell engineering tools and services for researchers in drug discovery and…
CRISPR-Cas9 is revolutionizing all facets of drug discovery, allowing for both a deeper understanding of…
A Q&A with Fady Riad, CEO of consulting company Centurion Life Sciences. How did CRISPR/Cas9…
ChristianaCare has spun out its first commercial biotech private start-up company, CorriXR Therapeutics. CorriXR Therapeutics…
On October 26 and 27 the Lithuanian capital, Vilnius, is hosting the European Forum for…